Betrixaban
Bevyxxa (betrixaban) is a small molecule pharmaceutical. Betrixaban was first approved as Bevyxxa on 2017-06-23. The pharmaceutical is active against coagulation factor X.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Betrixaban
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BEVYXXA | Portola Pharmaceuticals | N-208383 DISCN | 2017-06-23 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
217 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 20 | 16 | 17 | 20 | 8 | 78 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | 1 | 2 | 2 | 2 | 8 |
| Premature birth | D047928 | EFO_0003917 | O60 | 1 | 1 | 4 | 1 | — | 6 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | 3 | 1 | 1 | 5 |
| Oral lichen planus | D017676 | — | 2 | 1 | 1 | — | 4 | ||
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | 2 | 1 | 3 |
| Premature obstetric labor | D007752 | O60 | — | — | 2 | 1 | — | 3 | |
| Neck pain | D019547 | HP_0030833 | M54.2 | — | 1 | — | 1 | 1 | 3 |
| Back pain | D001416 | HP_0003418 | M54 | — | — | — | 2 | 1 | 3 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | 3 | — | 3 |
Show 29 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Newborn respiratory distress syndrome | D012127 | P22 | — | 2 | 1 | — | 1 | 3 | |
| Allergic rhinitis | D065631 | J30.9 | — | — | 2 | — | — | 2 | |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | 1 | 2 |
| Allergic contact dermatitis | D017449 | L23 | — | 1 | 1 | — | 1 | 2 | |
| Bronchiolitis | D001988 | HP_0011950 | — | 1 | 1 | — | — | 1 | |
| Contact dermatitis | D003877 | L25 | — | — | 1 | — | — | 1 | |
| Seborrheic dermatitis | D012628 | L21 | — | — | 1 | — | — | 1 | |
| Obstetric labor complications | D007744 | — | — | 1 | — | — | 1 | ||
| Oral submucous fibrosis | D009914 | K13.5 | — | — | 1 | — | — | 1 | |
| Cough | D003371 | HP_0012735 | R05 | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dry eye syndromes | D015352 | H04.12 | — | 2 | — | — | — | 2 | |
| Rotator cuff injuries | D000070636 | M75.1 | — | 2 | — | — | — | 2 | |
| Tennis elbow | D013716 | EFO_1001896 | M77.1 | — | 2 | — | — | — | 2 |
| Ankle injuries | D016512 | S93.4 | — | 1 | — | — | — | 1 | |
| Colorectal neoplasms | D015179 | — | 1 | — | — | — | 1 | ||
| Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | — | 1 | ||
| Melanoma | D008545 | — | 1 | — | — | — | 1 | ||
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 1 | 1 | — | — | — | 1 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 1 | — | — | — | 1 |
| Pterygium | D011625 | H11.0 | 1 | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Plantar fasciitis | D036981 | EFO_1001909 | M72.2 | 1 | — | — | — | 1 | 2 |
| Healthy volunteers/patients | — | 1 | — | — | — | 1 | 2 | ||
| Hypospadias | D007021 | EFO_0004209 | Q54 | 1 | — | — | — | — | 1 |
| Vasoconstriction | D014661 | 1 | — | — | — | — | 1 | ||
| Prostatitis | D011472 | EFO_0003830 | N41 | 1 | — | — | — | — | 1 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | — | — | — | — | 1 |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gout | D006073 | EFO_0004274 | M10 | — | — | — | — | 1 | 1 |
| Hypertrophic cicatrix | D017439 | L91.0 | — | — | — | — | 1 | 1 | |
| Cicatrix | D002921 | HP_0100699 | L90.5 | — | — | — | — | 1 | 1 |
| Keloid | D007627 | EFO_0004212 | L91.0 | — | — | — | — | 1 | 1 |
| Infant mortality | D007226 | — | — | — | — | 1 | 1 | ||
| Lichen planus | D008010 | L43 | — | — | — | — | 1 | 1 | |
| Hepatitis c | D006526 | B19.2 | — | — | — | — | 1 | 1 | |
| Vasculitis | D014657 | EFO_0006803 | M31 | — | — | — | — | 1 | 1 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | — | — | 1 | 1 |
| Lichen sclerosus et atrophicus | D018459 | L90.0 | — | — | — | — | 1 | 1 |
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BETRIXABAN |
| INN | betrixaban |
| Description | Betrixaban is a secondary carboxamide obtained by formal condensation of the carboxy group of 4-(N,N-dimethylcarbamimidoyl)benzoic acid with the amino group of 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide. A synthetic anticoagulant compound that targets activated factor Xa in the coagulation cascade. It has a role as an anticoagulant and an EC 3.4.21.6 (coagulation factor Xa) inhibitor. It is a member of guanidines, a member of benzamides, a secondary carboxamide, a monochloropyridine and a monomethoxybenzene. |
| Classification | Small molecule |
| Drug class | antithrombotics, blood coagulation factor XA inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)c1 |
Identifiers
| PDB | — |
| CAS-ID | 330942-05-7 |
| RxCUI | 1927851 |
| ChEMBL ID | CHEMBL512351 |
| ChEBI ID | — |
| PubChem CID | 10275777 |
| DrugBank | DB12364 |
| UNII ID | 74RWP7W0J9 (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 696 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9,223 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more